While Ascletis Pharmaceuticals Co. Ltd. aspires to discover its own drugs, it is employing a two-pronged strategy that includes in-licensing clinical candidates for the Chinese market. Its first external compound comes from Alnylam Pharmaceuticals Inc.

According to President and CEO Jinzi Wu, Chinese government support for life sciences has created an environment primed for biotech startups, expanding both the clinical research infrastructure and the talent pool in China, which enables novel drug discovery and development.